22:22 , Dec 5, 2017 |  BC Extra  |  Financial News

Heron raises $150M in follow-on

Heron Therapeutics Inc. (NASDAQ:HRTX) raised $150 million in a follow-on underwritten by Cantor Fitzgerald. The company markets Sustol granisetron extended release (APF530) to prevent chemotherapy-induced nausea and vomiting (CINV). The product is a long-acting formulation...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
21:21 , Jan 19, 2017 |  BC Extra  |  Financial News

Heron raises $150M in follow-on

Heron Therapeutics Inc. (NASDAQ:HRTX) raised $150 million through the sale of 12.3 million shares at $12.20 in a follow-on underwritten by BofA Merrill Lynch, Cowen, Leerink, Cantor Fitzgerald, JMP Securities, Noble Capital Markets, LifeSci Capital,...
22:15 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

Cinvanti regulatory update

Heron submitted an NDA to FDA for IV Cinvanti to prevent chemotherapy-induced nausea and vomiting (CINV). The company expects a decision in late 2017. Cinvanti is a polysorbate 80-free formulation of aprepitant, a tachykinin receptor...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....